Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1193 | Dexamethasone Wiki | 0.33 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.
Description: Clinical Improvement measured as the percentage of subjects at Day 14 who are in categories 1-3 according to the WHO 8-point Ordinal Scale for Clinical Improvement, comparing AZD1656 treatment to placebo
Measure: Clinical Improvement by Day 14 Time: Day 1 to Day 14Description: Clinical Improvement measured as the percentage of patients categorised at each severity rating on the WHO 8-point Ordinal Scale at Day 7, Day 14 and Day 21 versus baseline, comparing AZD1656 treatment with placebo.
Measure: *Title: Clinical Improvement at Day 7, 14 and 21 Time: Day 1 to Day 21Description: Degree of glycaemic control as measured by the need to increase baseline medication requirements or the need to add additional diabetic medications to maintain appropriate blood glucose levels in patients receiving AZD1656 compared with placebo
Measure: Glycaemic Control Time: Day 1 to Day 21Description: Proportion of Treatment Emergent Adverse Events (TEAEs) leading to study drug discontinuation in patients receiving AZD1656 compared with placebo
Measure: Occurrence of Adverse Events Time: Day 1 to Day 28Description: Proportion of Serious Adverse Events (SAEs) in patients receiving AZD1656 compared with placebo
Measure: Occurrence of Serious Adverse Events Time: Day 1 to Day 28Description: Time from hospital admission to hospital discharge (in hours) in patients receiving AZD1656 compared with placebo
Measure: Duration of Hospitalisation Time: Day 1 to Day 21Description: Time from hospital admission to receiving intubation/mechanical ventilation in patients receiving AZD1656 compared with placebo
Measure: Time to Intubation/ Mechanical Intervention Time: Day 1 to Day 21Description: Mortality rate in patients receiving AZD1656 compared with placebo.
Measure: Mortality Rate Time: Day 1 to Day 28Description: Plasma AZD1656 levels during first 7 days of treatment in patients receiving AZD1656 compared with placebo.
Measure: Pharmacokinetic Analysis Time: Day 1 to Day 7Description: Immunophenotyping panel to be conducted by Flow Cytometry: between group comparison (AZD1656 versus placebo)
Measure: Immunophenotyping Analysis Time: Day 1 to Day 21Description: Immunochemistry panel to be conducted using the Meso Scale Discovery (MSD) U-Plex multiplex assay.
Measure: Immunochemistry Analysis Time: Day 1 to Day 21Description: Measurement of hsTroponin and NTproBNP to determine extent of cardiac injury in patients receiving AZD1656 compared with placebo
Measure: Cardiac Injury Time: Day 1 to Day 21Description: Measurement of 25-hydroxyvitamin D levels before treatment to determine whether there is any correlation between baseline vitamin D level and clinical improvement in patients treated with AZD1656 versus placebo.
Measure: Correlation of clinical outcomes with pre-treatment vitamin D levels (by measurement of 25-hydroxyvitamin D levels). Time: Day 1 to Day 21Description: Sub group analysis of patient ethnicity, to determine whether there is any correlation between patient ethnicity and clinical improvement in patients treated with AZD1656 versus placebo.
Measure: Correlation of patient ethnicity with clinical improvement Time: Day 1 to Day 21Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports